Kidney disease may change how stiripentol works
NCT ID NCT05735951
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This completed phase 1 study looked at how the drug stiripentol behaves in people with mild, moderate, or severe chronic kidney disease compared to those with normal kidney function. Thirty-nine participants took stiripentol by mouth for 15 days. The goal was to see if kidney impairment alters drug levels in the blood, which could help determine if dose adjustments are needed.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stiripentol
What this could lead to
If successful, this study could help doctors adjust stiripentol doses for people with kidney problems, making the drug safer and more effective for them.
What could go wrong
This is a small, early-phase study focused on drug levels, not on treating any disease. Results may not change clinical practice without larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RENAL INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mc Comac Medical
Sofia, 1612, Bulgaria